Skip to main content
Vor Biopharma Inc. logo

Vor Biopharma Inc. — Investor Relations & Filings

Ticker · VOR ISIN · US9290331084 US Professional, scientific and technical activities
Open in API
Filings indexed 406 across all filing types
Latest filing 2022-12-16 Regulatory Filings
Country US United States of America
Listing US VOR

About Vor Biopharma Inc.

https://www.vorbio.com/

Vor Biopharma Inc. is a clinical-stage biotechnology company focused on developing treatments for autoimmune diseases. The company is committed to advancing medicines that target the fundamental drivers of autoimmunity, aiming to move beyond symptom control. Its lead candidate, telitacicept, is designed to silence the signals that allow harmful immune cells to survive. The company's objective is to deliver safer, longer-lasting therapies that address the source of autoimmune conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a letter from Vor Biopharma Inc. to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and is a formal request related to the registration process for securities. The document is short (1644 characters) and is a correspondence related to a capital raising filing, not the filing itself. This type of document is best classified as a Regulatory Filing (RNS) because it is a regulatory communication and does not contain financial statements, earnings data, or other report content. It is not a Capital/Financing Update (CAP) because it is a procedural request rather than an update on financing activities.
2022-12-16 English
Regulatory Filings 2022
Regulatory Filings
2022-12-16 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Vor Biopharma Inc. It is a registration statement under the Securities Act of 1933, used for registering securities for sale to the public. The text includes a preliminary prospectus describing the offering of common stock shares by a selling stockholder. It contains detailed information about the company, the securities being registered, risk factors, and other disclosures typical of a registration statement. This is not a financial report, earnings release, or management discussion, but a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, consistent with a registration statement filing.
2022-12-14 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically discusses the termination of a material definitive agreement related to an Open Market Sale Agreement for the company's common stock. It provides details about the termination date, the nature of the agreement, and the shares sold under it. This is an update on the company's financing activities, specifically the cessation of a sales agreement used for capital raising. The document is not a full financial report, earnings release, or management discussion, but rather an announcement about a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is 4016 characters, which is consistent with a detailed announcement rather than a brief notice or a full report.
2022-12-14 English
OWNERSHIP DOCUMENT
Director's Dealing
2022-12-09 English
SC 13D/A
Major Shareholding Notification
2022-12-09 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.